Rubinfeld Hadara, Hadani Moshe, Barkai Gad, Taylor John E, Culler Michael D, Shimon Ilan
Institute of Endocrinology and Metabolism, Rabin Medical Center, Beilinson Campus, Petach Tikva 49100, Israel.
J Clin Endocrinol Metab. 2006 Jun;91(6):2257-63. doi: 10.1210/jc.2005-2148. Epub 2006 Apr 4.
Cortistatin (CST) is a neuropeptide that shares high homology with somatostatin and binds with high affinity to all somatostatin receptor (SSTR) subtypes. Many of its endocrine and biological activities overlap with those of somatostatin.
OBJECTIVE/DESIGN: The objective of the study was to assess the direct in vitro effects of CST on human pituitary hormone secretion.
This study was performed in the endocrine laboratory of a tertiary academic medical center.
Primary cell cultures of human fetal (21-25 wk gestation) pituitary tissues and cultured hormone-secreting adenoma cells were used in this study.
Cell cultures were incubated with CST-14 or CST-17, somatostatin, GHRH, SSTR analogs, and ghrelin analogs, and hormone secretion was analyzed.
GH and prolactin (PRL) medium concentrations were tested by hormone assay, and SSTR mRNA was tested by RT-PCR.
CST-14 (10 nm) inhibited GH secretion by up to 65% in all fetal pituitary specimens after 4-h incubation (P < 0.05). CST-14 or CST-17 (10 nm) inhibited basal GH secretion in six of the 13 GH-cell adenomas and two of the three GH-PRL mixed adenomas. CST-17 (100 nm) suppressed the GH response to GHRH and ghrelin analog (10 nm each) by 30-50% in adenomas (P < 0.05). Three PRL-adenomas treated with CST-17 (10 nm) showed a 20-40% inhibition of PRL release (P < 0.05), whereas in three others no suppression or mild response was achieved at this concentration. A comparable inhibition of PRL secretion was obtained with SSTR5-selective analog but significantly less with SSTR2-preferential compounds. RT-PCR revealed the expression of both SSTR2 and SSTR5 in all GH-cell and mixed adenomas studied and all PRL-secreting adenomas studied, except for two of the CST-resistant prolactinomas, in which SSTR5 was absent.
This is the first report of in vitro CST suppression of human GH and PRL in cultured pituitary tissues. The regulation of PRL release from cultured adenomas appears to be primarily mediated by SSTR5.
促皮质素(CST)是一种与生长抑素具有高度同源性的神经肽,能与所有生长抑素受体(SSTR)亚型高亲和力结合。其许多内分泌和生物学活性与生长抑素重叠。
目的/设计:本研究的目的是评估CST对人垂体激素分泌的直接体外作用。
本研究在一家三级学术医学中心的内分泌实验室进行。
本研究使用了人胎儿(妊娠21 - 25周)垂体组织的原代细胞培养物和培养的激素分泌性腺瘤细胞。
将细胞培养物与CST - 14或CST - 17、生长抑素、生长激素释放激素(GHRH)、SSTR类似物和胃饥饿素类似物一起孵育,并分析激素分泌情况。
通过激素测定法检测生长激素(GH)和催乳素(PRL)的培养基浓度,通过逆转录聚合酶链反应(RT - PCR)检测SSTR mRNA。
孵育4小时后,CST - 14(10 nM)在所有胎儿垂体标本中抑制GH分泌高达65%(P < 0.05)。CST - 14或CST - 17(10 nM)在13个GH细胞腺瘤中的6个以及3个GH - PRL混合腺瘤中的2个中抑制基础GH分泌。CST - 17(100 nM)在腺瘤中使GH对GHRH和胃饥饿素类似物(各10 nM)的反应抑制30 - 50%(P < 0.05)。用CST - 17(10 nM)处理的3个PRL腺瘤显示PRL释放抑制20 - 40%(P < 0.05),而在另外3个中,在此浓度下未观察到抑制或仅有轻微反应。使用SSTR5选择性类似物可获得类似的PRL分泌抑制,但使用SSTR2优先化合物时抑制作用明显较小。RT - PCR显示,在所研究的所有GH细胞和混合腺瘤以及所有PRL分泌性腺瘤中均表达SSTR2和SSTR5,但有2个对CST耐药的催乳素瘤除外,其中不存在SSTR5。
这是关于体外CST抑制培养的垂体组织中人GH和PRL的首次报告。培养的腺瘤中PRL释放的调节似乎主要由SSTR5介导。